David Spigel, MD, is a medical oncologist and Chief Scientific Officer at the Sarah Cannon Research Institute, Nashville, TN.
Dr Spigel obtained his MD from The University of Tennessee, Knoxville, TN and subsequently completed a residency in internal medicine at Indiana University Medical Center, Indianapolis, IN. He subsequently carried out a fellowship in hematology and oncology at The Dana-Farber Cancer Institute, Boston, MA.
Speaking on predictive biomarkers and novel therapeutics for lung cancer
Dr Spigel’s research centers primarily on the development of chemotherapeutic agents for the treatment of lung cancer, in particular for non-small-cell lung cancer (NSCLC). He has been involved in several clinical trials, notably the Phase III PACIFIC trial (NCT02125461) which investigated the safety and efficacy of durvalumab after chemoradiotherapy in stage III NSCLC, as well as additional trials assessing rebastinib with carboplatin chemotherapy in mesothelioma.